Alzheimer Disease

Executive summary

Alzheimer's disease (AD) is by far the most common cause of dementia associated with aging; it accounts for more than 60% of all dementia. Alzheimer's disease is characterized by an insidious onset and slow deterioration in cognition, functional ability (e.g., activities of daily living), behavior, and mood. In USA, AD is the 7th leading cause of mortality. 
In 2010, more of 21 million people will be affected by this disease in the world. As the world population ages, this number will increase.
See also



Table of content

1 Global information
   1.1 History
   1.2 Presentation of the disease
   1.3 Patients with Alzheimer's disease forecast
   1.4 Prevalence

2 Alzheimer's disease
   2.1 Symptoms
   2.2 Physiopathology
   2.3 Risk factors
      Genetic affects
   2.4 Alzheimer's disease as a genetic disease
   2.5 Diagnosis

3 Market
   3.1 Overview
   3.2 Treatments and products
      Acetylcholinesterase inhibitors
      NMDA receptor antagonist
   3.3 Market previsions

4 Products in development
   4.1 Overview
   4.2 Products in phase III
      Immune Globulin Intravenous
      Leuprolide acetate implant
   4.3 Products in phase II

5 Pipeline of drugs for Alzheimer's disease, Discovery to Phase II
   5.1 Drugs in phase II
   5.2 Drugs in phase I
   5.3 Drugs in preclinical phase
   5.4 Drugs in discovery phase

6 Company profiles
   6.1 Baxter International Inc
   6.2 Bellus Health Inc
   6.3 Eisai Co Ltd
   6.4 Elan Corp Plc
   6.5 Eli Lilly and Co
   6.6 Forest laboratories Inc
   6.7 Johnson & Johnson
   6.8 Merz pharmaceutical
   6.9 Novartis Ag
   6.10 Pfizer Inc

List of Figures:

Figure 1: Estimated evolution of people with Alzheimer's disease 2010 to 2050 (in millions) by geographical zones
Figure 2: Progression of Alzheimer's disease (black dots)
Figure 3: Diagram of physiopathology mechanisms
Figure 4: Sales repartition by types of drugs
Figure 5: Sales repartition by geographical zones
Figure 6: Sales repartition by pharmaceutical companies
Figure 7: Therapeutic ways to treat Alzheimer's disease
Figure 8: Sales of marketed drugs by therapeutic classes
Figure 9: Sales distribution of Aricept in 2009
Figure 10: Estimated evolution of sales for Alzheimer's disease drugs for 2009 to 2020
Figure 11: Repartion of Alzheimer's drugs turnover for 2009 to 2020
Figure 12: Pipeline drugs in development in 2010
Figure 13: Clinical trials by development phases
Figure 14: Drugs in phase III by therapeutic classes
Figure 15: Drugs in phase II by therapeutic classes
Figure 16: Repartition of symptomatic treatments by mechanisms of action
Figure 17: Repartition of curative treatments by mechanisms of action

List of Tables:

Table 1: Total population over 65, estimated number of people with Alzheimer's disease from 2010 to 2020 (in millions) by geographical zones
Table 2: Incidence and prevalence on population aged 65 and over in 2010, 2015 and 2020 by geographical zones
Table 3: Main warning signs of Alzheimer's disease
Table 4: Common clinical features in Alzheimer's disease
Table 5: Potential risks and protective factors for Alzheimer's disease
Table 6: Differences between genetic disease and genetic susceptibility4
Table 7: Main brand-name drugs sold in the world
Table 8: Alzheimer's degree of severity treated by marketed drugs
Table 9: Current drug treatments for Alzheimer's disease
Table 10: Sales and forecast of main acetylcholinesterase inhibitor drugs
Table 11: Sales and forecast of main NMDA receptor antagonist drugs
Table 12: Drugs in phase III
Table 13: Alzheimer's degree of severity treated by drugs in phase III
Table 14: Clinical trials of Bapineuzumab
Table 15: Clinical trials of Dimebon
Table 16: Clinical trials of EGb-761
Table 17: Clinical trials of Gammagard (Immune Globulin Intravenous)
Table 18: Clinical trials of Memryte (leuprolide acetate implant)
Table 19: Clinical trials of LY-450139
Table 20: Clinical trials of Neramexane



Publication date: Number of pages: Price:
2010-06-01 70 3500 euros